Skip to content

ResMed RMD Short-Term Borrowings

Short-Term Borrowings at other companies

Pulmonx Corporation logo
Pulmonx CorporationLUNG
$104K-98.7%
Baxter International logo
Baxter InternationalBAX
$0-100%

Other financials

Income statement

See full
Revenue$1.4B+10.8%
Gross profit$891.0M+16.3%
Operating income$499.8M+17.3%
Net income$398.7M+9.2%
EPS (diluted)$2.74+10.5%

Balance sheet

See full
Cash & equivalents$1.7B+78.0%
Total debt$1.1B+29.8%
Total equity$6.5B+17.1%
Total assets$8.8B+16.1%

Cash flow

See full
Operating cash flow$554.1M-4.2%
CapEx$33.7M+61.8%
Free cash flow$520.5M-6.7%

Valuation

See full
Market cap$28.27B-19.1%
Enterprise value$27.71B-19.8%
P/E18.6×-6.3×
P/S5.1×-1.7×

Profitability

See full
Gross margin61.6%+2.8pp
Operating margin34.2%+2.1pp
Net margin27.4%+1.3pp
FCF margin31.7%+0.4pp

Returns & leverage

See full
Return on equity25.2%-0.6pp
Debt / equity0.2×0.0×
Current ratio-0.4×

Where this comes from

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:ShortTermBorrowings.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's short-term borrowings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ResMed's short-term borrowings?
ResMed (RMD) reported short-term borrowings of $259.93M in Q1 2026.
How has ResMed's short-term borrowings changed year-over-year?
ResMed's short-term borrowings increased by 2523.9% year-over-year, from $9.91M to $259.93M.
What is the long-term trend for ResMed's short-term borrowings?
Over 4 years (2021 to 2025), ResMed's short-term borrowings has grown at a -4.7% compound annual growth rate (CAGR), from $12M to $9.9M.
What does short-term borrowings mean?
Bank lines of credit, revolving credit facilities, and other short-term debt instruments with maturities under one year.